Wandercraft Secures $75M to Propel AI-Driven Humanoid Robotics and Exoskeletons
Wandercraft, a Paris-based leader in robotic mobility solutions, has recently secured $75 million in Series C funding to fast-track the development and commercialization of its AI-powered humanoid robots and advanced exoskeletons. This milestone investment positions Wandercraft at the forefront of next-generation assistive technologies, promising to revolutionize rehabilitation and mobility for individuals with walking impairments.
The funding round attracted global interest and was co-led by Quadrant Management, Eurazeo, and Bpifrance. Additional contributions came from Credit Mutuel Innovation, LBO France, and the European Investment Bank. This robust backing highlights growing confidence in the transformative potential of artificial intelligence in the realm of robotics.
Wandercraft is best known for creating the world’s first autonomous, self-balancing walking exoskeleton, currently used in major hospitals for neurological rehabilitation. Their flagship product, Atalante, leverages real-time AI algorithms to restore natural walking patterns and supports therapy for conditions such as stroke, spinal cord injury, and multiple sclerosis. The company’s upcoming projects target the development of personal exoskeletons for broader home and community use.
A representative from Wandercraft conveyed the company’s overarching mission: “Our ambition is to deliver mobility for all, regardless of age or physical condition.” The involvement of high-profile investors marks a pivotal moment, aligning Wandercraft’s innovative approach with unprecedented financial resources.
The new capital injection will enable Wandercraft to scale production, expand its footprint in the U.S. market, and advance research in both software and hardware. The company plans to bolster its AI platform, which is crucial for dynamic adaptation to complex, real-world walking scenarios. Researchers will continue to focus on enhancing the human-machine interface and developing intuitive controls to improve user experience.
Investors recognize Wandercraft’s global potential in transforming healthcare and mobility. With the world’s population aging, the role of exoskeletons and humanoid robots is expected to grow. These technologies not only improve quality of life for patients but also ease the burden on care providers and facilities.
Wandercraft’s achievements underscore Europe’s ambition to become a leader in robotics innovation. With $75 million in fresh capital, the coming years could see Wandercraft’s AI-powered solutions bridging the gap between clinical rehabilitation and daily mobility, setting a new standard in human assistance.
Team V.INO-LNK
